In the latest trading session, Astrazeneca (AZN) closed at $201.21, marking a -1.55% move from the previous day. This move ...

Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.

AstraZeneca (NASDAQ: AZN) stock finished the trading week in style, rising by nearly 3% in value on Friday. That was due to news from the company that it's expanding its manufacturing footprint in the ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astrazeneca (AZN) is a stock that can certainly grab the attention of many investors ...

The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or ...

AstraZeneca is driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched. See why AZN stock is a buy.

Early this morning, AstraZeneca shared the results of a phase 3 clinical trial of baxdrostat, its investigational drug for treatment-resistant hypertension (i.e., high blood pressure). Where to invest ...

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...

AstraZeneca ( (GB:AZN)) has shared an update. AstraZeneca shareholders overwhelmingly approved all resolutions at the 9 April 2026 Annual General Meeting, including reappointment of KPMG as auditor, ...

The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland. 10 stocks we like better than AstraZeneca Plc › ...